“Our findings demonstrate that the CD6-ALCAM pathway is crucial in modulating effector T cell function, and inhibition of CD6 signaling with itolizumab can modulate multiple effector T cell ...

Putterman: Itolizumab is currently being evaluated in patients with SLE and lupus nephritis as part of the EQUALISE trial, which is testing whether specifically blocking the CD6-ALCAM pathway can ...

Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while ...

In addition, itolizumab demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, a leading indicator of drug activity, consistent with its mechanism of action.

Title: Antigenic Modulation of CD6 By Itolizumab Is a New Mechanism for Effector T Cell Inhibition First Author: Dalena Chu, Senior Research Associate, Equillium, Inc., Session Name: 203.

Itolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of the pathogenic ...

Itolizumab treatment significantly reduced the trans-endothelial migration of pathogenic T cells, with high correlation of effector T cells’ migration index with the CD6 levels on the cell surface.

Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases.

Throughout this program you will learn more about: CD6/ALCAM pathway and its role in immuno-inflammation Contribution of the CD6/ALCAM pathway in the pathogenesis of SLE and lupus nephritis Mechanism ...

Equillium has developed itolizumab, a first-in-class anti-CD6 monoclonal antibody therapy to prevent the pathogenesis of lupus. Cherie Ng, the senior director for research at Equillium, tells us more ...

Itolizumab, a novel humanized monoclonal antibody to CD6, was found to be an effective, well-tolerated treatment for moderate-to-severe psoriasis, according to study data. The phase 3, randomized ...